Regeneron brings its antibody chops to gene editing’s biggest problem

TARRYTOWN, NY — For over three decades, Regeneron has been synonymous with one thing in the drug industry: antibodies. Blockbusters like Dupixent, Eylea, and Covid-19 antibodies have transformed what started as a scrappy startup into one of biotech’s biggest names.

But the billionaire co-founders who still run the $91 billion…
Click here to view original post